Erythromycin
- Atc Codes:D10AF02#J01FA01#S01AA17
- CAS Codes:114-07-8
- PHARMGKB ID:114-07-8
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Eryaknen, Eryfluid, Erystad, Erythrocin, Erythromycin, Meromycin; Belgium: Acneryne, Aknemycin, Erythrocine, Erythroforte, Inderm, Stimycine; Bulgaria: Acnerin, Erythran; Cyprus: Ermyced, Ermycin, Erythran, Porphyrocin, Stiemycin; Czech Republic: Aknefug-EL, Aknemycin, Eryfluid; Denmark: Abboticin, Erycin, Escumycin, Hexabotin; Estonia: Aknefug-EL; Finland: Abboticin, Ermysin; France: Abboticine, Egery, Ery, Eryacne, Eryfluid, Erithrocine, Erhytrogel, Erythromycine, Stimycine; Germany: Akne Cordes, Aknederm Ery Gel, Aknefug-EL, Aknemago, Aknemycin, Ery, Eryaknen, Erybeta TS, Erycinum, Erydermec, Eryfluid, EryHEXAL, Erykanen, Erysec, Erythro-CT, Erythrocin, Erythromycin, Erytrotil, Hydrodermed Ery, Inderm, Infectomycin, Paediathrocin forte, Sanasepton; Greece: Acne Hermal, Dankit, Eritromicina, Erycinum, Erygel, Erythrocin, Erythromycin, Erythropen; Hungary: Aknefug-EL, Aknemycin, Erythromycin, Erythrotrop, Meromycin; Ireland: Erymax, Erythrocin, Erythromycin, Erythroped, Primacine, Stiemycin; Italy: Eritro E, Eritro L, Eritro S, Eritrocina, Eritromicina, Eryacne, Lauromicina; Latvia: Aknefug-EL, Erythromycin, Porphyrocin; Lithuania: Aknefug-EL, Erythromycin; Luxembourg: Acneryne, Akne-Mycin, Aknemycin, Ery, Eryderm, Eryfluid, EryHEXAL, Erythro, Erythrocine, Erythromycin, Erythromycine, Ilosone, Inderm, Macromycine, Monomycin, Stiemycin; Malta: Erythromycin, Primacine, Stiemycin; Netherlands: Erytrolyve; Poland: Acnecin, Aknemycin, Davercin, Erythromycinum; Portugal: Akne-Mycin, Clinac, Eritrazon, Eritrocel, Eritrocina, Eryfluid; Romania: Eritromagis, Eritromicina, Eryfluid; Slovakia: Aknefug-EL, Aknemycin, Eryfluid, Erythromycin, Inderm; Slovenia: Eritromicin; Spain: Bronsema, Deripil, Eridosis, Eritrogobens, Eritromicina, Eritroveinte, Euskin, Lagarmicin, Loderm, Pantomicina; Sweden: Abboticin, Ery-Max; UK: Eryacne, Erymax, Erythrocin, Erythromycin.
North America
Canada: AK Mycin Oph ONT, Diomycin, Erybid, Eryc, Erysol, Erythro, Erythrocin, Erythromycin; USA: Akne-Mycin, E-Glades, E.E.S., Ery-Tab, Eryc, Erygel, EryPed, Erythra-Derm, Erythro-Statin, Erythrocin, Erythromycin, PCE, Pediamycin.
Latin America
Argentina: Algiderm, Atlamicin, Clarex, Eri, Erigrand, Erisine, Erisol, Erit Bioquin, Eritrofarm, Eritromed, Eritromicina, Eritrovis, Eryacne, Etisux, Iloticina, Kitacne, Oftalmolets, Pantomicina, Pentoclave, Toperit, Trixne, Wemid; Brazil: Eribiotic, Eritrex, Eryacnen, Ilosone, Kanazima, Pantomicina, Stiemycin, Valmicin-Eritromicina; Mexico: Apo-Trina, Bestocin, Biotril, Eribec, Eriber, Erisuspen, Eritrolat, Eritromicina, Eritrosol, Eritrovier, Eritrowel, Eryacnen, Eryderm, Erylar, Iliocin, Ilosin, Iqfamicina, Lantrom, Latotryd, Lauricin, Lauritran, Optomicin, Pantomicina, Pertrosom, Procephal, Promicin, Quimolauril, Sansascne, Stiemycin, T-Stat, Witromin.
Asia
Japan: Elislit, Erythrocin, Erythromycin.
Drug combinations
Erythromycin and Benzoyl Peroxide
Erythromycin and Bromhexine
Erythromycin and Colismethate
Erythromycin and Ethanol
Erythromycin and Isotretinoin
Erythromycin and Sulfisoxazole
Erythromycin and Tretinoin
Erythromycin and Zinc
Chemistry
Erythromycin: C~37~H~67~NO~13~. Mw: 733.93. (1)(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. CAS-114-07-8.
Pharmacologic Category
Antibacterials; Macrolides; Erythromycins. EENT Preparations; Antibacterials. Skin and Mucous Membrane Agents; Antibacterials. Acne Product. (ATC-Code: D10AF02; J01FA01; S01AA17).
Mechanism of action
A macrolide antibiotic. Inhibits RNA-dependent protein synthesis at the chain elongation step. Binds to the 50S ribosomal subunit resulting in blockage of transpeptidation.
Therapeutic use
Treatment of susceptible bacterial infections including S. pyogenes, some S. pneumoniae, some S. aureus, M. pneumoniae, Legionella pneumophila, diphtheria, pertussis, Chlamydia, erythrasma, N. gonorrhoeae, E. histolytica, syphilis and nongonococcal urethritis, and Campylobacter gastroenteritis. Used in conjunction with neomycin for decontaminating the bowel. Treatment of superficial eye infections involving conjunctiva or cornea. Neonatal ophthalmia. Treatment of acne vulgaris.
Pregnancy and lactiation implications
No adequate, well-controlled studies completed in pregnant women. The estolate form of erythromycin should not be used in pregnancy due to a potential increased risk for hepatic toxicity. Caution if administered to breast-feeding women.
Unlabeled use
Treatment of gastroparesis, chancroid. Preoperative gut sterilization.
Contraindications
Hypersensitivity to erythromycin or any component of the formulation. Concomitant use with pimozide or cisapride.
Warnings and precautions
Macrolides associated with rare QTc prolongation and ventricular arrhythmias, including torsade de pointes (use with caution in risk of prolonged cardiac repolarization). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in pre-existing liver disease; hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, observed. Associated with aggravation of weakness associated with myasthenia gravis. High potential for drug interactions exists (use caution with any agents with substantial metabolism through the CYP3A4 pathway). Use of erythromycin associated with infantile hypertrophic pyloric stenosis. The elderly may be at increased risk of adverse events, including hearing loss and/or torsade de pointes when dosage ≥4 g/day, particularly if concurrent renal/hepatic impairment.